Coronary Artery Disease, also called CAD, is a cardiovascular disease caused by diminished or missing blood flow in the arteries that encircle and supply the heart, also known as Ischemia.
New York, July 06, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Coronary Heart Disease Diagnostic Imaging Devices Market Size, Share & Industry Trends Analysis Report By Modality, By Regional Outlook and Forecast, 2022 – 2028” – https://www.reportlinker.com/p06289224/?utm_source=GNW
A dense layer of cholesterol, fat, and calcium develops a thick layer in the walls of arteries in a coronary artery, restricting blood flow.
Owing to a decrease in blood flow caused by coronary artery disease, the myocardial cell begins to die due to a lack of oxygen. Chest pain, heartburn, and soreness in the shoulder, arm, back, and neck are all symptoms of coronary artery disease. Coronary CT angiography, cardiac magnetic resonance imaging, and radionuclide modalities, such as single proton emission computed tomography (SPECT), positron emission tomography (PET), and PET/CT are the most common coronary artery imaging modalities. The image is enhanced with a variety of contrasting agents. CT pictures are commonly enhanced with iodine-based contrast agents, while MRI images are enhanced with gadolinium. In CT scans, radio-opaque iodine contrast dye is commonly administered through coronary arteries.
The most common symptoms of CAD are angina, chest pain, and discomfort. If too much volume increases inside arteries, they become narrow and cause angina. Blood flow to the heart muscle as well as the rest of the body might be blocked by narrowed arteries, which can cause chest pain. excess weight, inactivity, bad eating habits, and cigarette consumption are all risk factors for coronary artery disease. A family history of heart disease, particularly a family history of heart disease at an early age also raises the risk of CAD. Anyone healing from a heart failure, heart attack, or another heart disease that necessitated surgery or medical treatment may consider cardiac rehabilitation (rehab). Cardiac rehab can assist these people to improve their quality of life and prevent another heart attack.
Following the advent of the COVID-19 pandemic, CHD screening in hospitals, diagnostic centers, as well as ambulatory centers decreased. Any diagnostic or surgical actions in end-use settings were also halted due to concerns about virus transmission. This subsequently resulted in a financial crisis in hospitals, clinics, diagnostic centers, and other end-user settings, affecting newer installations. The diagnostic market was further affected by the suspension of diagnostic centers and a preference for solely diagnosing COVID-19-related tests. National closures, a halt in logistics, an economic downturn, a shift in focus to develop a treatment protocol, such as virtual care and tele-visits, and a shift in focus to establish a treatment protocol, like virtual care and tele-visits, all had an impact on new product launches and developmental activities.
Market Growth Factors
Rising incidences of cardiac diseases
The rise in cardiovascular disease incidence has enhanced the demand and expansion of cardiovascular ultrasonography. Cardiovascular imaging ultrasonography technologies, such as echocardiography and sonograms, are widely used to diagnose and monitor cardiovascular disorders like coronary artery disease, peripheral artery disease, congenital heart disease, atherosclerosis, and arrhythmia, among others. In the next years, the growth in incidence of cardiovascular illness is anticipated to stimulate the demand for cardiovascular ultrasound equipment.
Rising number of applications of the imaging device along with increasing R&D investments
Cardiovascular ultrasound technologies and display devices are widely utilized for a variety of purposes. By combining the system’s performance with a powerful, software-based beamformer image reconstruction platform, a 2D cardiovascular ultrasound system can help to reduce non-diagnostic examination. Because of features like real-time imaging, accelerating procedural time and installing technology, advanced cardiac quantification, and improved clinical efficiencies, 3D and 4D cardiovascular ultrasound systems are widely used for echocardiographic imaging for treating and tracking cardiovascular and heart disorders.
Market Restraining Factors
High cost of the product
Coronary heart disease diagnostic imaging devices are prohibitively expensive for low-budget healthcare organizations to purchase. This could pose a major challenge to the development of the coronary heart device diagnostic imaging device market. Moreover, poverty levels in various developing and underdeveloped countries have reached unacceptably high levels. People living in poverty and suffering from many types of cardiovascular ailments find it challenging to afford cardiovascular ultrasonography, limiting the prospects for the market players. Moreover, due to the integration of various advanced and latest technologies, the manufacturing cost of these devices also become higher, which is directly impacting the demand for these imaging devices in various low-income healthcare facilities.
Based on Modality, the market is segmented into Nuclear Medicine, Computed Tomography, Ultrasound, X rays, and Magnetic Resonance Imaging. In 2021, the Nuclear Medicine segment procured the highest revenue share of the market. Non-invasiveness, image clarity, precise illness identification even at an early stage, and rising adoption among end-users are the factors attributed to the rising growth of this segment. Unlike any other modality, a huge number of radiologists are properly trained to use the nuclear medicine instrument and read the image precisely.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America accounted for the largest revenue share of the coronary heart disease imaging device market. The growth of the regional market is increasing due to several factors, such as the presence of technically advanced medical staff, improved government healthcare expenditure, an increase in the number of cancer cases, and an increase in the obesity ratio in contrast to other nations, as well as increased research and development activities.
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Koninklijke Philips N.V., Siemens Healthineers AG , Fujifilm Holdings Corporation , Canon, Inc. are the forerunners in the Coronary Heart Disease Diagnostic Imaging Devices Market. Companies such as General Electric (GE) Co. and Mindray Medical International Limited are some of the key innovators in theMarket.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Koninklijke Philips N.V., Siemens Healthineers AG, Fujifilm Holdings Corporation, Canon, Inc. (Canon Medical Systems Corporation), Mindray Medical International Limited, Chison Medical Technologies Co., Ltd., and Analogic Corporation (Altaris Capital Partners).
Recent Strategies Deployed in Coronary Heart Disease Diagnostic Imaging Devices Market
Partnerships, Collaborations and Agreements
Jul-2021: Canon came into a partnership with Cleerly, a digital healthcare company. Under this partnership, the companies would facilitate simple and streamlined adoption of cardiac CT and introduce new standards of heart disease care.
Mar-2021: Royal Philips partnered with DiA Imaging Analysis, a leader in providing AI-powered applications for the ultrasound. Following this partnership, the companies would offer automated solutions to clinicians at the point of care. Additionally, Philips’s high image quality in combination with the AI library of automated solutions of DiA Imaging Analysis would help increase operational efficiency, diagnostic confidence, and access to care for Point-of-Care customers everywhere.
Nov-2020: GE Healthcare partnered with GenesisCare, a leading vendor of integrated cancer care. Through this partnership, the companies aimed to enhance the diagnosis of heart diseases and cancer. In addition, the companies would integrate GenesisCare’s cancer and cardiac screening, treatments, and diagnosis delivery capabilities into the best-in-class digital infrastructure, oncology and cardiology solutions, and imaging technologies.
Product Launches and Product Expansions
Feb-2022: Fujifilm unveiled its premium Sonosite LX system, an addition to its next-generation POCUS offerings. The new product would offer the largest clinical image and monitor of the company that rotates, tilts, and extends in order to provide improved and real-time provider collaboration.
Feb-2022: Siemens Healthineers introduced Artis icono biplane, an angiography system. The new product would offer the latest features for treating and diagnosing coronary heart disease, arrhythmia, and structural heart disease. In addition, the new product would also streamline clinical workflows and offer best-in-class quality at a low radiation dose.
May-2021: Mindray unveiled Mindray’s General Imaging ultrasound solutions, new Women’s Healthcare, General Imaging, and Cardiology ultrasound solutions. The new solutions are equipped with several cutting-edge technologies, such as comprehensive HiFR elastography, high frame rate contrast-enhanced ultrasound, and enhanced quantification measurement to set new standards of image clarity.
Sep-2020: Siemens Healthineers released a new version of its c.cam, a new version of its c.cam across the US market. The new product is a single-photon emission computed tomography scanner along with a reclining patient chair in order to offer a low total cost of ownership to nuclear cardiology practitioners.
Jul-2020: Canon launched the Aquilion One / Genesis SP, an addition to its Aquilion One / Genesis Edition. The new product aimed to meet the evolving requirements of coronary and structural imaging in order to enable high-quality and consistent studies via its AI-powered wide-area CT.
Acquisitions and Mergers
Nov-2021: Royal Philips took over Cardiology, a french medical technology company. This acquisition aimed to strengthen Royal Philips’s cardiac monitoring and diagnostics portfolio with Cardiologs’s electrocardiogram (ECG) analysis and reporting services.
Feb-2021: Royal Philips acquired BioTelemetry, a leader in remote cardiac diagnostics and monitoring devices. This acquisition aimed to complement Royal Philips’s cardiac care portfolio along with its vision to transform the delivery of care.
Approvals and Trials
Oct-2020: GE Healthcare received the US FDA approval for its Ultra Edition package on Vivid cardiovascular ultrasound systems. The new product includes various new artificial intelligence-based functions in order to offer faster and more repeatable evaluations consistently.
Scope of the Study
Market Segments covered in the Report:
• Nuclear Medicine
• Computed Tomography
• X rays
• Magnetic Resonance Imaging
• North America
o Rest of North America
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
• General Electric (GE) Co. (GE Healthcare)
• Koninklijke Philips N.V.
• Siemens Healthineers AG
• Fujifilm Holdings Corporation
• Canon, Inc. (Canon Medical Systems Corporation)
• Mindray Medical International Limited
• Chison Medical Technologies Co., Ltd.
• Analogic Corporation (Altaris Capital Partners)
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06289224/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001